Is the price fair?
What NVO's price assumes
Novo Nordisk A/S did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 0.22× revenue.
0.22
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.12
Price / book · as of 2025-FY
- EV / sales
- 0.32
EV / sales
Details›
- Price / book2025-FY
- 1.12
- EV / EBIT2025-FY
- 0.74
- EV / sales2025-FY
- 0.32
- Market capitalisation
- $191.2B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #4 of 16 by Smart Score